Evidence map›Paper›PMID 37600402›Full record

ArticleHeliyon2023

Factors associated with listing for lung transplantation in IPF patients: An analysis of the pulmonary fibrosis foundation registry.

Christopher S King, Emily White, Shambhu Aryal, Oksana A Shlobin, Anju Singhal, A Whitney Brown, Christopher Thomas, Vikramjit Khangoora, Alan Nyquist, Kevin R Flaherty and 2 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Christopher S KingAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Emily WhiteUniversity of Michigan, Department of Biostatistics, USA.
Shambhu AryalAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Oksana A ShlobinAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Anju SinghalAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
A Whitney BrownAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Christopher ThomasAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Vikramjit KhangooraAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Alan NyquistAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Kevin R FlahertyUniversity of Michigan Division of Pulmonary & Critical Care Medicine, USA.
Steven D NathanAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Joshua J MooneyStanford University, Division of Pulmonary and Critical Care Medicine, USA.
Inova Fairfax Hospital · USUniversity of Michigan · USStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale and objectives: Lung transplantation is a potentially life-saving treatment option for patients with idiopathic pulmonary fibrosis (IPF); however, not all eligible candidates get referred and listed for transplantation. Amongst IPF patients within the Pulmonary Fibrosis Foundation Patient Registry (PFF-R), we sought to determine the proportion of patients who undergo lung transplant listing and the characteristics associated with transplant listing. Methods: An analysis of IPF patients with at least six months of follow-up data was performed. Patients with well-established contraindications to lung transplantation were excluded. Two complementary analyses were performed. The "prevalent" population included all patients with IPF at time of enrollment into the registry. The "incident severe" population included all patients with IPF who progressed to GAP Stage 3. Results: Of the 2003 patients in the PFF-R, 475 patients were included in the "prevalent" population. Of this group, only 42 (8.8%) were either listed for or underwent lung transplant. Univariable analysis of the "prevalent" population found age (per 10 year increase, OR 0.531, p = 0.0025), percent predicted FVC (OR 0.572, p=<0.0001), percent predicted DLCO (OR 0.606, p < 0.0001), 6-min walk distance (per 50 m, OR 0.831, p = 0.019), and oxygen use at rest (OR 5.157, p < 0.0001) were predictive of listing. On multivariable analysis, age (per 10 year increase, OR 0.558, p = 0.0088), percent predicted FVC (OR 0.728, p = 0.0161), and oxygen use at rest (OR 3.264, p = 0.0029) remained significant predictors for lung transplant listing. The "incident severe" group consisted of 176 patients (8.8%). 24 patients (13.6%) from this cohort were either listed for or received a transplant. Only age (per 10 year increase, OR 0.0286, p = 0.0465) was associated with transplant listing on univariable analysis in the Incident severe population. Conclusion: Only a small proportion of potentially eligible patients with IPF are listed for lung transplantation, even when seen at pulmonary fibrosis centers of excellence. Advanced age appears to be the primary factor associated with failure to be listed. Further refinement of future registry data is required to more clearly delineate exact reasons for low rates of listing.

Indexed as

Idiopathic pulmonary fibrosisLung transplantationPulmonary fibrosis

Identifiers

PMID37600402
PMCPMC10432603
OpenAlexW4385566452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.